REG - IP Group PLC - Pulmocide announces termination of Phase 3 study

IPAnnouncement

Wed 14:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260107:nRSG0378Oa&default-theme=true

RNS Number : 0378O  IP Group PLC  07 January 2026

 FOR RELEASE ON  07 January 2026

 

 

Portfolio company Pulmocide announces termination of Opera-T Phase 3 study
with Opelconazole

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in
breakthrough science and innovation companies with the potential to create a
better future for all, notes the announcement from portfolio company Pulmocide
Ltd ("Pulmocide" or "the Company") that it has taken the decision to terminate
its Opera-T Phase 3 Study with opelconazole in refractory Invasive Pulmonary
Aspergillosis (IPA).

 

Pulmocide, a biopharmaceutical company in which IP Group has a 12.0% holding
valued at £28.1m, will be conducting a thorough review of the unblinded data
from this trial to determine potential next steps for the program. As a
result, the Group expects to significantly reduce the carrying value of this
asset and will conduct further work as part of the year end process to fully
evaluate the appropriate level of this adjustment.

 

IP Group benefits from a strong pipeline of new and maturing companies, as
well as a number of valuable licences, and remains confident of delivering
meaningful returns for shareholders over the medium term.

 

For more information, please contact:

 

 IP Group plc                       www.ipgroupplc.com
 Liz Vaughan-Adams, Communications  +44 (0) 20 7444 0062/+44 (0) 7967 312125
 Portland
 Alex Donaldson                     +44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most
active UK based, early stage science investor, we develop and support some of
the world's most exciting businesses in deeptech, life sciences and cleantech.
Through Parkwalk, the UK's largest growth EIS fund manager, we also back
world-changing innovation emerging in leading universities and research
institutions. Our specialist investment team combines sector expertise with an
international approach. Together we have a strong track record of success,
having backed high-profile companies including Oxford Nanopore Technologies
plc, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on
the Main Market of the London Stock Exchange under the code IPO. For more
information, please visit our website at www.ipgroupplc.com
(http://www.ipgroupplc.com/) .

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUBRSRNUUARAR



            Copyright 2019 Regulatory News Service, all rights reserved